Clinical Helpline ๐Ÿ“ž Oncology Clinical Helpline (Monโ€“Sat 9:00 AM โ€“ 6:00 PM IST): +91 22 31846644 • ICMR 2023 Safety Standards
MDT Collaboration DICOM Web Viewer Genomic Biomarkers

Virtual Tumor Board Software for Multidisciplinary Cancer Review (MDT)

Convene cross-specialty tumor boards with surgical, medical, and radiation oncologists, radiologists, and pathologists in a unified digital cockpit.

Convene Tumor Board โ†— Schedule Panel Walkthrough
Evidence-Based Consensus

Streamline Complex Oncology Case Discussions

Eliminate fragmented WhatsApp groups and email chains. Consolidate PET-CT scans, histopathology slides, and molecular genetics in one secure environment.

๐Ÿ”ฌ

PACS & DICOM Zero-Footprint Viewer

Inspect CT, MRI, and PET scans directly within the browser with multi-planar reconstruction, window leveling, and measurement tools.

๐Ÿงฌ

Molecular Genomics & Biomarkers

Highlight actionable mutations (EGFR, ALK, KRAS, BRCA, HER2) with direct links to targeted therapy clinical trials and guidelines.

๐Ÿ“

Consensus Documentation

Generate structured, sign-off-ready MDT summary notes that automatically link to the patient's EMR and ABHA record.

Clinical Decision Concordance

NCCN vs. ICMR Guideline Concordance Framework for Digital MDTs

Multidisciplinary Tumor Boards in India frequently navigate clinical divergence between resource-intensive international NCCN guidelines and the Indian Council of Medical Research (ICMR) consensus protocols tailored for resource-stratified care.

๐Ÿงฌ Molecular Biomarker & NGS Gating

While NCCN mandates routine broad-panel NGS in advanced NSCLC, ICMR prioritizes reflex single-gene PCR for actionable EGFR (Exon 19/21) and IHC for ALK before costly panels. OncoCare supports tiered biomarker tagging so panels can select appropriate lines of therapy based on financial and insurance eligibility.

๐Ÿ’Š Generic & Biosimilar Equivalence

In accordance with ICMR oncology consensus, OncoCareโ€™s regimen builder seamlessly incorporates DCGI-approved biosimilars (Trastuzumab, Bevacizumab, Rituximab) alongside originator biologics, allowing tumor boards to record cost-conscious treatment pathways without compromising clinical efficacy.

๐Ÿ“‘ Formal Multidisciplinary Consensus Dossier

The platform compiles individual recommendations from Medical, Surgical, and Radiation Oncologists into a single signed MDT dossier. The consensus notes rationale for regimen selection, intent (curative, neoadjuvant, or palliative), and planned reassessment intervals.

Clinical Governance Note: All tumor board documentation strictly complies with National Medical Commission (NMC) professional conduct standards and the ICMR Biomedical AI Ethical Charter (2023). Multi-disciplinary panel consensus is recorded under the treating cliniciansโ€™ individual digital sign-offs.

Ready to Transform Oncology Care in Your Practice?

Empower your oncology care teams, medical oncologists, and chemotherapy patients with real-time monitoring and ABDM-compliant health records.

Access Patient App โ†— Launch Doctor EMR โ†— Schedule Hospital Demo